The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists
Diabetes Care · 2026
DOI: 10.2337/dc26-0662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Hyunsuk Lee und 21 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: SNU-SNUH Physician Scientist Training Program, Ministry of Food and Drug Safety, NIDDK NIH HHS.
Abstract (Originalsprache)
OBJECTIVE Genetic variation in the glucagon-like peptide 1 receptor (GLP1R) has been implicated in type 2 diabetes (T2D) risk and treatment response. We investigated whether GLP1R R131Q, which was previously reported as a T2D-protective variant in genome-wide association studies, alters receptor signaling, β-cell function, and response to glucagon-like peptide 1 receptor agonists (GLP-1RAs). RESEARCH DESIGN AND METHODS Trajectory of β-cell function was evaluated in a 20-year community-based prospective cohort in Korea (n = 6,373), where participants underwent biennial 2-h 75-g oral glucose tolerance tests, and disposition index was used as surrogate marker. Pharmacogenetic response to GLP-1RAs was assessed in a hospital-based T2D cohort in Korea (n = 177). Hyperglycemic clamp studies (n = 17), human islet experiments (n = 21), and in vitro assays were conducted to characterize GLP1R R131Q effects on receptor signaling and islet function. RESULTS GLP1R R131Q was associated with slower decline in disposition index in individuals without T2D, with reductions from baseline of 30% in homozygous carriers, 35% in heterozygotes, and 37% in wild-type individuals. In people with T2D, each allele conferred an additional 0.53% or 5.8 mmol/mol reduction in HbA1c after 6 months of GLP-1RA treatment (P = 5.8 × 10−4). Hyperglycemic clamp and human islet experiments demonstrated allele-dependent enhancement of GLP-1RA–stimulated insulin secretion (P = 0.050 and P = 0.037, respectively). In vitro, GLP1R R131Q increased GLP-1RA–stimulated cAMP production with directional observations consistent with pathway bias. CONCLUSIONS GLP1R R131Q is a gain-of-function variant associated with preservation of β-cell function and enhanced glycemic response to GLP-1RA treatment, supporting further investigation as a candidate pharmacogenetic marker for precision diabetes care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genomic Medicine Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Division of Endocrinology, Diabetes & Metabolism, Mayo Clinic College of Medicine, Rochester, MN.
- Department of Internal Medicine, Konkuk University Medical Center, Seoul, Republic of Korea.
- Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Hyunsuk Lee, Hannah E Christie, Min Kyong Moon, Sung Hee Choi, Dae Ho Lee, Federica Boscolo, Chiara Dalla Man, Nam H Cho, Jaewon Choi, Adrian Vella, Soo Heon Kwak, Jong-Il Kim, Kyong Soo Park
Förderung
- SNU-SNUH Physician Scientist Training Program
- Ministry of Food and Drug Safety
- NIDDK NIH HHS
- Ministry of Science and ICT, South Korea
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Lee, H., Christie, H. E., Lee, J. S., Kwon, W. I., Moon, M. K., Choi, S. H., Lee, D. H., Lee, S., Lee, H., Kho, M., Boscolo, F., Dalla Man, C., Cho, N. H., Choi, J., Lee, J., Park, J., Jo, Y., Lee, S., Vella, A., …, & Park, K. S. (2026). The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists. Diabetes Care. https://doi.org/10.2337/dc26-0662
Vancouver
Lee H, Christie HE, Lee JS, Kwon WI, Moon MK, Choi SH, et al. The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists. Diabetes Care. 2026. doi:10.2337/dc26-0662
BibTeX
@article{Lee2026,
author = {Lee, Hyunsuk and Christie, Hannah E and Lee, Ji Seon and Kwon, Woo-Il and Moon, Min Kyong and Choi, Sung Hee and Lee, Dae Ho and Lee, Seunggeun and Lee, Hyunbeom and Kho, Minjung and Boscolo, Federica and Dalla Man, Chiara and Cho, Nam H and Choi, Jaewon and Lee, Jeongeun and Park, Jongseok and Jo, Yeeun and Lee, Sangwon and Vella, Adrian and Kwak, Soo Heon and Kim, Jong-Il and Park, Kyong Soo},
title = {The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc26-0662}
}
EUVIMED